Week 10 Pharm HF
docx
keyboard_arrow_up
School
Wilkes University *
*We aren’t endorsed by this school
Course
533
Subject
Medicine
Date
Dec 6, 2023
Type
docx
Pages
2
Uploaded by DukeEchidnaPerson924
Heart failure can be classified into various stages and types based on several factors. The
most used classification systems for heart failure are the New York Heart Association (NYHA)
functional classification and the American College of Cardiology/American Heart Association
(ACC/AHA) staging system. According to the NYHA Functional Classification system, this
patient would be Class III. Patients diagnosed with heart failure are markedly limited in their
abilities to carry out physical activity. Patients classified as class III are comfortable at rest but
symptomatically short of breath with less than ordinary physical activity. The AHA classifies
heart failure into four stages based on structural heart damage. This patient would be classified as
Stage C, which is broken into two categories— heart failure with a preserved ejection fraction
(HFpEF, ejection fraction > 45%) and heart failure with reduced ejection fraction (HFrEF,
ejection fraction < 45%) (Pattison, 2019). These patients can be placed into these categories
based on their left ventricle’s ability to pump or relax and fill with blood. To improve this
patient’s symptoms, discontinue ibuprofen. The American College of Cardiology
Foundation/American Heart Association HF guidelines recommend that this class of drugs
should be avoided or withdrawn whenever possible (Pagell et al., 2016). HCTZ can also be
increased to 25 mg daily to help control her edema if her blood pressure is not too low. The
monitoring parameters I recommend include degree of breathlessness, heart rate, blood pressure
and weight gain. It is important to have patients with heart failure weigh themselves wearing the
same clothes they slept in each morning after urinating and prior to eating or drinking anything.
The non-pharmacologic recommendations I have for this patient are to limit their sodium intake
by following a heart-healthy, DASH diet, performing light physical activity as tolerated, not
drinking alcohol or smoking, limiting caffeine consumption, and practicing stress relief activities
including meditation, guided imagery, or mindful breathing (Chisholm-Burns et al., 2022)\.
To manage this 79-year-old African American woman with a history of hypertension,
transient ischemic attack (TIA) and gout uncontrolled hypertension, a comprehensive treatment
plan should be implemented. Gout is a type of arthritis caused by the buildup of uric acid crystals
in the joints of the body. A diagnosis of gout is correlated with a higher risk of hypertension and
cardiovascular disease. The diagnosis of gout in this patient underlines the necessity for
efficacious blood pressure control because uncontrolled hypertension can worsen the symptoms
of gout, increasing the risk of gout flares (Chisholm-Burns, 2022). In addition to
pharmacotherapy, this patient should implement lifestyle modifications such as adopting a
healthy diet low in sodium and high in fruits, vegetables, and whole grains, getting regular
exercise, managing weight, and limiting alcohol consumption (Chisholm-Burns, 2). According to
the American College of Cardiology/American Heart Association hypertension guidelines,
combination drug therapy for most African Americans diagnosed with hypertension, in addition
to those with blood pressure >20/10 mm Hg above target blood pressure and those with stage 2
hypertension. However, thiazide-like diuretics for example chlorthalidone, indapamide are
preferred over thiazide-type diuretics for example, hydrochlorothiazide, and there is a single-pill
combination available that combines an ACE inhibitor with a thiazide-like diuretic, for example
perindopril-indapamide (Flack & Buhnerkempe, 2022). Tracking blood pressure regularly is
important to ensure it is well-controlled. The patient should also be educated about the
importance of adhering to the treatment plan and attending regular follow-up appointments with
her healthcare provider. Overall, managing uncontrolled hypertension in this African American
female patient with a history of TIA and gout requires a comprehensive approach that includes
lifestyle modifications, medication management, and regular monitoring to reduce the risk of
complications and improve her overall health. It is recommended that if you are taking
benazepril you should be advised to avoid moderately high or high potassium dietary intake. This
can cause elevated serum potassium levels. Additionally, the patient should be educated not to
use salt substitutes or potassium supplements while taking benazepril unless your doctor has told
you to. When taking benazepril with aspirin, you should check your blood pressure regularly and
may need your kidney function monitored.
References
Chisholm-Burns, M. A., Schwinghammer, T. L., Malone, P. M., Kolesar, J. M., Lee, K. C.,
Bookstaver, P.B. (2022). Pharmacotherapy: Principles and practices (6th edition).
McGraw-Hill Education. ISBN 978-1-260-46027-8
Flack, J. M., Buhnerkempe, M. G. (2022). ace and antihypertensive drug therapy: Edging
closer to a new paradigm.
https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.121.18545
Pattison, K. H. (2019). Medications for heart failure management: What nurses need to know:
Learn about heart failure medications to ensure improved outcomes.
American Nurse
Today
, 14(2), 20–23.
Pagell, R. L., O’Bryant, C. L., Cheng, D., Dow, T. J., Ky, B., Stein, C. M., Spencer, A. P. Trupp,
R. J., Lindenfeld, J. (2016). Drugs that may cause or exacerbate heart failure | circulation.
https://www.ahajournals.org/doi/10.1161/CIR.0000000000000426
Your preview ends here
Eager to read complete document? Join bartleby learn and gain access to the full version
- Access to all documents
- Unlimited textbook solutions
- 24/7 expert homework help
Related Documents
Anthem_Silver_Pathway_X_Guided_Access_HMO_6500_S06_0_Virtual_PCP_0_Select_Drugs_GA_HMO_Individual_6R
Anthem_Silver_Pathway_X_Guided_Access_HMO_5800_40_Standard_S06_GA_HMO_Individual_758T_01_01_2023_Eng